At iSeek Biopharma, we unite science, medicine, and business to transform nuclear medicine through precision diagnostics and therapies. Our focus is advancing solutions for infections, inflammatory diseases, and hematologic cancers with greater accuracy and efficiency.
Drawing on decades of radiopharmaceutical innovation, clinical development, and commercialization, we are delivering molecular imaging and therapeutic tools that enable earlier detection, more effective treatment, and better outcomes for patients worldwide.
At the core of this vision is our proprietary, first-in-class PET agent, designed with high specificity for LFA-1 receptors on leukocytes. This breakthrough provides real-time visualization of immune cell trafficking, redefining how infection, inflammation, and disease are identified and managed.
